{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06023576",
            "orgStudyIdInfo": {
                "id": "23-159"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study of Blood Pressure Control During Cancer Treatment",
            "officialTitle": "Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT), A Randomized Controlled Trial",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-of-blood-pressure-control-during-cancer-treatment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-18",
            "studyFirstSubmitQcDate": "2023-08-29",
            "studyFirstPostDateStruct": {
                "date": "2023-09-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure levels and the risk of cardiotoxicity in patients with cancer. Other studies have shown lowering blood pressure improves the health of patients. However, these studies have not included people with cancer.\n\nThe PROTECT trial is testing a treatment strategy regarding intensive versus standard SBP goals, and is not testing specific medications."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Cardiotoxicity"
            ],
            "keywords": [
                "Blood pressure",
                "23-159"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This open-label, two-arm RCT will compare the effects of intensive versus standard SBP control in patients with BC and HTN receiving anthracycline-based treatment (with or without HER2-targeted therapy).",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 130,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "standard-of-care antihypertensive medications",
                    "type": "EXPERIMENTAL",
                    "description": "SBP control will consist of treatment with antihypertensive medications titrated every 4 weeks for the first 3 months, and then every 3 months in months 4-12. SBP control will be achieved by titration of antihypertensive medications based upon a standardized algorithm and will be implemented during a 12-month study period. At the time of randomization, no antihypertensive treatments may be initiated or modified if SBP is \u2265160 mm Hg. The clinical context may be considered at each visit to inform decision-making regarding treatment initiation or modification, at the discretion of the treating provider.",
                    "interventionNames": [
                        "Other: antihypertensive medications",
                        "Diagnostic Test: Blood pressure measurement",
                        "Diagnostic Test: Echocardiogram",
                        "Other: Symptom-limited cardiopulmonary exercise test",
                        "Other: Quality of Life Measures",
                        "Diagnostic Test: Biomarkers"
                    ]
                },
                {
                    "label": "higher dose antihypertensive medications",
                    "type": "EXPERIMENTAL",
                    "description": "Patients randomized to intensive SBP control will be treated to achieve an SBP goal \\<120 mm Hg, and patients randomized to standard SBP control will be treated to achieve an SBP goal \\<140 mm Hg. Antihypertensive medications will be titrated on the basis of seated blood pressure measurements obtained after a 5-min rest period. All participants will be provided with dietary (e.g., 1500mg/d sodium restriction) and lifestyle recommendations as background therapy for optimizing HTN control.The clinical context may be considered at each visit to inform decision-making regarding treatment initiation or modification, at the discretion of the treating provider.",
                    "interventionNames": [
                        "Other: antihypertensive medications",
                        "Diagnostic Test: Blood pressure measurement",
                        "Diagnostic Test: Echocardiogram",
                        "Other: Symptom-limited cardiopulmonary exercise test",
                        "Other: Quality of Life Measures",
                        "Diagnostic Test: Biomarkers"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "antihypertensive medications",
                    "description": "One or more of the following medications may be used in both randomization groups to achieve SBP goals:\n\n* Angiotensin converting enzyme inhibitors (ACEI)\n* Angiotensin receptor blockers (ARBs)\n* Beta-blockers (BB)\n* Thiazide-type diuretics\n* Calcium channel blockers\n* Aldosterone antagonists\n* Alpha1-receptor blockers.\n* Direct vasodilators\n* Loop diuretics",
                    "armGroupLabels": [
                        "higher dose antihypertensive medications",
                        "standard-of-care antihypertensive medications"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Blood pressure measurement",
                    "description": "Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).",
                    "armGroupLabels": [
                        "higher dose antihypertensive medications",
                        "standard-of-care antihypertensive medications"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Echocardiogram",
                    "description": "At baseline, month 6, and month 12",
                    "armGroupLabels": [
                        "higher dose antihypertensive medications",
                        "standard-of-care antihypertensive medications"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Symptom-limited cardiopulmonary exercise test",
                    "description": "Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.",
                    "armGroupLabels": [
                        "higher dose antihypertensive medications",
                        "standard-of-care antihypertensive medications"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Quality of Life Measures",
                    "description": "FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.",
                    "armGroupLabels": [
                        "higher dose antihypertensive medications",
                        "standard-of-care antihypertensive medications"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Biomarkers",
                    "description": "Research blood samples will be collected at baseline, 3 months, and 6 months",
                    "armGroupLabels": [
                        "higher dose antihypertensive medications",
                        "standard-of-care antihypertensive medications"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "mean change in systolic blood pressure (SBP) from baseline to 12 months",
                    "description": "based upon in-office measurement",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* Female assigned at birth\n* Biopsy proven breast cancer (stage I-IV)\n* Treatment with therapy anthracycline-based chemo (with or without HER2-targeted therapy), with \\>/= 2 cycles of anthracycline chemotherapy planned.\n* SBP \u2265130 mm Hg\n* Willing and able to comply with the requirements of the protocol.\n* Participant must have and be willing to use their bluetooth enabled wifi or cellular mobile device\n* (For participants in the CPET cohort): Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria:\n\n  * Achieving a plateau oxygen consumption, concurrent with an increase in power output;\n  * A respiratory exchange ratio \u2265 1.10;\n  * Attainment of maximal predicted heart rate, as defined by a peak heart rate within 10bpm of the age predicted maximal heart rate (220 - Age\\[years\\]);\n  * Volitional exhaustion, as measured by a rating of perceived exertion (RPE) \u2265 18 on the BORG scale.\n\nExclusion Criteria:\n\n* eGFR \\< 30 ml/min/1.73m2 (based upon Cockcroft-Gault, etc.)\n* Individuals with arm circumference too large to allow accurate BP measurement with available BP devices\n* Inability to accurately measure blood pressure in at least one arm (e.g., bilateral upper extremity lymphedema)\n* Cardiac comorbidity, including any of the following:\n\n  * Acute coronary syndrome within 3 months prior to randomization.\n  * Symptomatic heart failure (NYHA class III/IV) within past 6 months\n  * History of stroke\n  * Cardiac transplantation\n* Other medical disorder or condition that in the opinion of the investigator would impair the subject's ability to participate or adhere to study interventions\n* (For participants in the CPET cohort): Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing:\n\n  * Acute myocardial infarction (within 30 days of any planned study procedures),\n  * Unstable angina\n  * Uncontrolled arrhythmias causing symptoms or hemodynamic compromise,\n  * Symptomatic severe aortic stenosis\n  * Recurrent syncope\n  * Active endocarditis\n  * Acute myocarditis or pericarditis\n  * Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures)\n  * Thrombosis of lower extremities (within 3 months of any planned study procedures)\n  * Suspected dissecting aneurysm\n  * Uncontrolled asthma\n  * Pulmonary edema\n  * Room air desaturation at rest \u226485%\n  * Respiratory failure\n  * Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)\n  * Mental impairment leading to inability to cooperate.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "genderDescription": "Female assigned at birth",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anthony Yu, MD",
                    "role": "CONTACT",
                    "phone": "212-639-7932",
                    "email": "yua3@mskcc.org"
                },
                {
                    "name": "Jennifer Liu, MD",
                    "role": "CONTACT",
                    "phone": "212-639-8220"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Anthony Yu, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Basking Ridge",
                    "state": "New Jersey",
                    "zip": "07920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70621,
                        "lon": -74.54932
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Monmouth (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Bergen (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Montvale",
                    "state": "New Jersey",
                    "zip": "07645",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.04676,
                        "lon": -74.02292
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Westchester (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center (All Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Nassau (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Rockville Centre",
                    "state": "New York",
                    "zip": "11553",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.65871,
                        "lon": -73.64124
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org/mskcc/html/44.cfm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000066126",
                    "term": "Cardiotoxicity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000064420",
                    "term": "Drug-Related Side Effects and Adverse Reactions"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000011832",
                    "term": "Radiation Injuries"
                },
                {
                    "id": "D000014947",
                    "term": "Wounds and Injuries"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30670",
                    "name": "Cardiotoxicity",
                    "asFound": "Cardiotoxicity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M30303",
                    "name": "Drug-Related Side Effects and Adverse Reactions",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14679",
                    "name": "Radiation Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "asFound": "90%",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5384",
                    "name": "Calcium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4134",
                    "name": "Angiotensin-Converting Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M28916",
                    "name": "Angiotensin Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M3671",
                    "name": "Adrenergic beta-Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M7411",
                    "name": "Diuretics",
                    "relevance": "LOW"
                },
                {
                    "id": "M17412",
                    "name": "Vasodilator Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                }
            ]
        }
    },
    "hasResults": false
}